Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Market Cap	32.38B -14.7%
Revenue (ttm)	3.75B +29.1%
Net Income	-501.48M
EPS	-0.50
Shares Out	1.03B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,133,800
Open	16.17
Previous Close	15.72
Day's Range	15.80 - 16.35
52-Week Range	14.80 - 30.80
Beta	0.64
Analysts	Buy
Price Target	28.21 (+76.98%)
Earnings Date	Oct 29, 2026

About HKG:1877

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 3,055
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1877

Financial Performance

In 2025, HKG:1877's revenue was 2.50 billion, an increase of 28.23% compared to the previous year's 1.95 billion. Losses were -875.17 million, -31.68% less than in 2024.

Financial numbers in CNY

Analyst Summary

According to 4 analysts, the average rating for 1877 stock is "Buy." The 12-month stock price target is $28.21, which is an increase of 76.98% from the latest price.

Price Target

$28.21

(76.98% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error